Physician profile

Ruby P Huttner

Obstetrics & Gynecology · Flemington, NJ

NPI 1053366146

$397.44

in general payments reported to CMS, 2019-2025

11 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$24.97

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Allergan, INC. $120.66 2019
Abbvie INC. $66.12 2021-2022
Mayne Pharma Commercial LLC $52.38 2022-2023
Therapeuticsmd, INC. $43.40 2019-2022
Pfizer INC. $27.39 2020-2022
Evofem Biosciences, INC. $15.31 2021
Lupin INC. $15.00 2021
Daiichi Sankyo INC. $14.99 2020
Medtronic, INC. $14.98 2021
Astellas Pharma US INC $14.23 2023 Myrbetriq
Amag Pharmaceuticals, INC. $12.98 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Ruby P Huttner

$397.44

in general payments reported 2019-2025

Years
2019-2023
Top company
Allergan, INC.

https://glasscript.com/doctor/183993/ruby-p-huttner

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.